AstraZeneca completes Summit investment and AstraZeneca stock trades at EUR 142.63
Published on 10/12/2026 at 10:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- AstraZeneca completed a USD 2.0 billion equity investment in Summit Therapeutics on October 5, 2026.
- The investment is intended to accelerate development of ivonescimab with AstraZeneca cancer medicines.
- AstraZeneca stock was trading at EUR 142.63 at Lang & Schwarz on October 12, 2026 at 10:44 a.m. CEST.
- Jefferies maintained a Buy rating and a GBp 17,500 price target on October 7, 2026.
AstraZeneca (ISIN GB0009895292) was trading at EUR 142.63 at Lang & Schwarz on October 12, 2026 at 10:44 a.m. CEST. The company had completed a USD 2.0 billion equity investment in Summit Therapeutics on October 5, 2026, according to AstraZeneca.
What does the Summit deal add?
The investment is designed to accelerate development of ivonescimab, a PD-1 and VEGF bispecific antibody, in combination with antibody-drug conjugates across tumor types. Summit Therapeutics said on October 5, 2026 that AstraZeneca bought approximately 108,955 preferred shares convertible into common stock at a 1:1,000 ratio.
The transaction gives AstraZeneca an oncology pipeline position while leaving Summit responsible for development and commercial rights to ivonescimab. The financial scale is material against AstraZeneca's quarterly revenue of GBP 11.46 billion for the quarter ended June 30, 2026, which was 5.84 percent higher than the comparable period, according to finanzen.ch.
Three dated milestones
AstraZeneca's recent sequence began with the June 30, 2026 quarter, when revenue reached GBP 11.46 billion. On September 28, 2026, the companies announced the USD 2.0 billion investment, and on October 5, 2026, AstraZeneca completed it, according to Summit Therapeutics. The chronology ties the latest corporate action to a reported revenue base rather than treating the investment as a standalone headline.
Analyst view and upcoming dates
Jefferies maintained a Buy rating and a GBp 17,500 price target on October 7, 2026, while expecting third-quarter revenue 1.00 percent above Visible Alpha consensus and core earnings before interest and tax 3.00 percent above expectations, as Proactive reported.
The next dated company events are the ESMO Meet the Management event on October 26, 2026, listed by AstraZeneca, and the expected third-quarter results on October 30, 2026, reported by finanzen.ch.
Stock trades during London session
AstraZeneca stock was trading at EUR 142.63 at Lang & Schwarz on October 12, 2026 at 10:44 a.m. CEST. The primary listing is on the London Stock Exchange, where the share trades in GBp and belongs to the FTSE 100.
The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.
AstraZeneca stock facts
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN.L
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz as of October 12, 2026, 10:44 a.m. CEST: EUR 142.63
- Sector / Industry: Healthcare / Drug Manufacturers
- Index membership: FTSE 100
Market context: Market report FTSE 100.
